Bristol-Myers Squibb’s Hepatitis B Therapy Baraclude Will Be Available April 8
This article was originally published in The Pink Sheet Daily
Executive Summary
Entecavir clears FDA after a six-month priority review. Baraclude labeling includes data showing superior efficacy versus GlaxoSmithKline’s Epivir-HBV. Bristol will detail the product to the 3,500 physicians who treat most U.S. cases of hepatitis B using a Baraclude-specific sales force.
You may also be interested in...
Bristol’s Baraclude Beats Hepsera In Two-year Trial
Potent rival Viread aims to shake up hepatitis B market.
Bristol’s Baraclude Beats Hepsera In Two-year Trial
Potent rival Viread aims to shake up hepatitis B market.
Baraclude Bests Hepsera On Viral Load Reduction In HBV Patients – Bristol Study
Study shows that 58 percent of Baraclude-treated patients achieved undetectable viral load at 48 weeks versus 19 percent taking adefovir.